3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
2
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
2
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
1387
Neoplasms
1164
Colorectal Neoplasms
624
Lung Neoplasms
559
Prostatic Neoplasms
538
Carcinoma, Non-Small-Cell Lung
443
Carcinoma, Hepatocellular
296
Stomach Neoplasms
272
Pancreatic Neoplasms
270
Colonic Neoplasms
264
Ovarian Neoplasms
230
Head and Neck Neoplasms
228
Rectal Neoplasms
221
Melanoma
215
Multiple Myeloma
202
Uterine Cervical Neoplasms
198
Lymphoma
195
Leukemia
193
Precursor Cell Lymphoblastic Leukemia-Lymphoma
191
Neoplasm Metastasis
178
Carcinoma, Renal Cell
177
Esophageal Neoplasms
173
Brain Neoplasms
173
Leukemia, Myeloid, Acute
158
Urinary Bladder Neoplasms
138
Recurrence
123
Polycystic Ovary Syndrome
122
Liver Neoplasms
118
Hematologic Neoplasms
117
Endometrial Neoplasms
107
Interventions
darolutamide
1
Docetaxel
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Observational
×
Metastatic Hormone-sensitive Prostate Cancer
×
Clear all
NCT06498921
2024-10-24
BELBEQA
Bayer
Completed
106 enrolled